Immutep Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
|Primary activities||biotechnology and medical research|
|Industry / Sector||Biotechnology / Healthcare|
|Mailing address||Australia Square Level 33 264 George Street Sydney NSW 2000 Australia|
|Phone / Fax||/|
|Share registry||BOARDROOM PTY LIMITED|
Immutep does not pay dividends.
As of Jan 2022, following are the company executives and directors listed on Immutep.
|Mr. Marc Voigt||CEO, MD, CFO, Chief Bus. Officer & Exec. Director||48||556.7k|
|Ms. Deanne Miller LLB||COO, Gen. Counsel & Joint Company Sec.||44||365.48k|
|Dr. Frederic Triebel M.D., Ph.D.||Chief Scientific Officer & Chief Medical Officer||66||553.41k|
|Ms. Indira Naidu||Joint Company Sec.|
|Mr. Christian Mueller||Director of Clinical Devel. & Regulatory Affairs|
|Mr. Shengfei Fang||Fin. Director & Assistant Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Immutep is and its enterprise value is .
The IMM's stocks Beta value is 1.54 making it 54% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Immutep (IMM)
Immutep (ASX:IMM) Frequently Asked Questions
1. What is Immutep's Stock Symbol?
Immutep trades on ASX under the ticker symbol "IMM".
2. What is Immutep's stock price today?
One share of IMM stock can currently be purchased for approximately $0.455.
3. How can I contact Immutep?
Immutep's mailing address is Australia Square Level 33 264 George Street Sydney NSW 2000 Australia. The company can be reached via phone at .
4. What is Immutep's official website?
The official website of Immutep is https://www.immutep.com.
5. Which share registry manages Immutep's stock?
Immutep's stock is managed by BOARDROOM PTY LIMITED.